metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-13 EVALUATION OF UNDIAGNOSED ALCOHOLIC LIVER DISEASE IN PATIENTS WITH METABOLI...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Full text access
P-13 EVALUATION OF UNDIAGNOSED ALCOHOLIC LIVER DISEASE IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE USING THE ANI SCORE
Visits
55
Carlos Alventosa Mateu1, Mercedes Latorre Sánchez1, Inmaculada Castelló Miralles1, Benjamín Climent Díaz2, Juan José Urquijo Ponce1, Moisés Diago Madrid1
1 Hepatology Unit, Digestive Diseases Department, Consorcio Hospital General Universitario of Valencia, Valencia, España
2 Toxicology Unit, Internal Medicine Department, Consorcio Hospital General Universitario of Valencia, Valencia, España
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2024 Annual Meeting of the ALEH

More info
Conflict of interest

No

Introduction and Objectives

The 2024 EASL-EASD-EASO guidelines on Steatotic Liver Disease emphasize the distinction between Metabolic Dysfunction-Associated Steatotic Liver Disease (MAFLD) and the subcategories with significant alcohol consumption: Alcoholic Liver Disease (ALD) and Metabolic ALD (MetALD). To this aim, a systematic record of alcohol consumption and/or validated biomarkers is recommended.

To evaluate the likelihood of associated but unrecognized alcohol-related liver disease (MetALD/ALD) in patients managed for MAFLD.

Patients / Materials and Methods

A single-center retrospective study that analyzes the probability of MetALD/ALD using the ALD/NAFLD (ANI) score in patients diagnosed with MAFLD during May/June 2024. MAFLD was defined by the presence of hepatic steatosis with alcohol intake <20/30 g/day (iwomen/men), at least one cardiovascular risk factor, and no other discernible cause. Patients with suspected advanced chronic liver disease were excluded. A probability of MetALD/ALD was considered if ANI>0 (indicative of a probability >50%). Sociodemographic variables, alcohol consumption, and hepatic fibrosis were recorded and compared between the ANI>0 and ANI<0 groups, with significance level set at p<0.05.

Results and Discussion

85 patients were included, average age 61.8±9.7 years, 52.9% male. Alcohol consumption was documented in medical history for 63.3% (54/85) of patients, with 53.4% (29/54) reporting no consumption. Per ANI score, 21.2% (18/85) were identified as having a probability of MetALD/ALD (ANI>0), with half of these (9/18) showing a probability >90%. Alcohol intake (10-20/30 g/day) was significantly higher in the ANI>0 group, consisting solely of males. Hepatic fibrosis was more pronounced in this group (7.6±3.6 vs 5.9±1.7) but did not reach statistical significance.

Conclusions

The significant prevalence of unrecognized MetALD/ALD by ANI score suggests that alcohol consumption may be underreported in the ANI>0 group. Therefore, the inclusion of the ANI score as a biomarker for accurate differentiation MAFLD from MetALD/ALD appears to be beneficial.

Full Text

Comparison of ANI>0 and ANI<0 groups.

Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos